Meneghini Vasco Ricercatore tempo determinato tipo aMedicine

FORMAZIONE

 

2010           Ph.D. in Biotecnologie Farmaceutiche ed Alimentari - Università del Piemonte Orientale “A. Avogadro”, Novara, Italy

 

2006           Laurea Specialistica in Biotecnologie Industriali - Università degli studi Milano-Bicocca, Milano, Italy

 

2003           Laurea Triennale in Biotecnologie Molecolari - Università degli studi Milano-Bicocca, Milano, Italy

 

ATTIVITÀ DIDATTICA-ACCADEMICA

 

2022           Ricercatore t. det. (RTD-A) - BIO/17 ISTOLOGIA, 5/H2 ISTOLOGIA - Facoltà di Medicina e Chirurgia, Libera Università Vita-Salute San Raffaele, Milan, Italy

 

2021           Professore a contratto, - SSD BIO/14 - Corso di Laurea Magistrale in Biotecnologie Farmaceutiche, Dipartimento di Scienza del Farmaco, Università del Piemonte Orientale “A. Avogadro”, Vercelli, Italy

 

ATTIVITÀ DI RICERCA

 

2019           Project Leader, Gene and Neural Stem Cell Therapy for Lysosomal Storage Diseases Unit, San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget), Milan, Italy

 

2014           Postdoctoral Fellow, Laboratory of Chromatin and Gene Regulation during Development - INSERM UNIT U1163 - Imagine Institute of Genetic Diseases, Hôpital Necker-Enfants maladies, Paris, France

 

2011           Postdoctoral Fellow, Gene and Neural Stem Cell Therapy for Lysosomal Storage Diseases Unit - San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget), Milan, Italy

                  

2006           Ph.D. student and Postdoctoral Fellow, Laboratory of Neuroplasticity and Neuropathic Pain - University of Piemonte Orientale “A. Avogadro”, Novara, Italy

                  

PREMI e RICONOSCIMENTI

 

2022           NextGenerationEU-PNRR grant, Italian Ministry of University and Research

2022           BGTC AAV Biology research program (Co-PI), Foundation for the National Institutes of Health

2020           Marie Skłodowska Curie Actions (MSCA), Individual Fellowship - Horizon 2020

2019           Ricerca Finalizzata - Giovani Ricercatori 2019, Italian Ministry of Health

2019           Sanofi iAwards Europe 2019 (Co-PI)

2016           PRESTIGE COFUND European Union FP7 - Campus France

2006           National PhD Fellowship, Italian Ministry of Health and Research

 

PUBLICAZIONI SCIENTIFICHE

 

1.  Cantore A., Fraldi A., Meneghini V., Gritti A. In vivo Gene Therapy to the Liver and Nervous System: Promises and Challenges. Front Med (Lausanne). 2022 Jan 18; 8:774618.

 

2. Ramadier S., … , Meneghini V.*, Miccio A.* Combination of lentiviral and genome editing technologies for the treatment of sickle cell disease. Mol Ther. 2022 Jan 5; 30(1):145-163. *Co-last and co-corresponding authors.

 

3.  Meneghini V.*, Peviani M., Zambonini G., Luciani M, Gritti A. Delivery Platforms for CRISPR/Cas9 Genome Editing of Glial Cells in the Central Nervous System. Front Genome Ed. 2021 Mar 3; 3:644319. *Corresponding author. Review.

 

4. Luciani M, Gritti A, Meneghini V.*. Human iPSC-Based Models for the Development of Therapeutics Targeting Neurodegenerative Lysosomal Storage Diseases. Front Mol Biosci. 2020 Sep 18; 7:224. *Corresponding author. Review.

 

5. Romano O., Petiti L., Felix T., Meneghini V., et al. GATA factor-mediated gene regulation in human erythropoiesis. iScience 2020 Mar 30;23(4):101018.

 

6. Weber L, Frati G, Felix T, Hardouin G, Casini A, Wollenschlaeger C, Meneghini V, et al. Editing a gamma-globin repressor binding site restores fetal hemoglobin synthesis and corrects the sickle cell disease phenotype. Sci Adv. 2020 Feb 12;6(7): eaay9392.

 

7. Lattanzi A., Meneghini V., et al. Optimization of CRISPR/Cas9 Delivery to Human Hematopoietic Stem and Progenitor Cells for Therapeutic Genomic Rearrangements. Mol Ther. 2019 Jan 2;27(1):137-150.

 

8. Frati G., Luciani M., Meneghini V., et al. Human iPSC-based models highlight defective glial and neuronal differentiation from neural progenitor cells in metachromatic leukodystrophy. Cell Death Dis. 2018, 9(6):698.

 

9. Antoniani C.*, Meneghini V.*, et al. Induction of fetal hemoglobin synthesis by CRISPR/Cas9-mediated editing of the beta-globin locus. Blood. 2018 Apr 26;131(17):1960-1973. *Co-first authors.

Commentary on Blood Journal: A chance to cut (the genome) is a chance to cure. Kara E. Montbleau and Vijay G. Sankaran. Blood 2018 131:1884-1885.

 

10. Meneghini V.*, Frati G.*, et al. Generation of Human Induced Pluripotent Stem Cell-Derived Bona Fide Neural Stem Cells for Ex Vivo Gene Therapy of Metachromatic Leukodystrophy. Stem Cells Transl Med. 2017 Feb;6(2):352-368. *Co-first authors.

 

11. Meneghini V., et al. Pervasive supply of therapeutic lysosomal enzymes in the CNS of normal and Krabbe-affect non-human primates by intracerebral lentiviral gene therapy. EMBO Mol Med. 2016 May 2;8(5):489-510.

 

12. Meneghini V., et al. The noradrenergic component in Tapentadol action counteracts MOR-mediated adverse effects on adult neurogenesis. Mol Pharmacol. 2014 May;85(5):658-70.

 

13. Meneghini V., et al. High-mobility group box-1 protein and beta-amyloid oligomers promote neuronal differentiation of adult hippocampal neural progenitors via receptor for advanced glycation end products/nuclear factor-kB axis: relevance for Alzheimer's disease. J Neurosci. 2013 Apr 3;33(14):6047-59.

 

14. Meneghini V., et al. A novel role for the Receptor for Advanced Glycation End-products in neural progenitor cells derived from adult SubVentricular Zone. Mol Cell Neurosci. 2010, 45(2):139-50.

 

15. Meneghini V., Odent S., Platonova N., Egeo A., Merlo G.R. Novel TBX3 mutation data in families with Ulnar-Mammary syndrome indicate a genotype-phenotype relationship: mutations that do not disrupt the T-domain are associated with less severe limb defects. Eur J Med Genet. 2006 Mar-Apr; 49(2):151-8.

 

 

EDUCATION

 

2010           Ph.D. in Food and Pharmaceutical Biotechnologies - University of Piemonte Orientale “A. Avogadro”, Novara, Italy

 

2006           Master Degree in Industrial Biotechnology - University of Milan-Bicocca, Milano, Italy

 

2003           Bachelor in Molecular Biotechnology - University of Milan-Bicocca, Milano, Italy

 

PROFESSIONAL EXPERIENCES

 

2022           Fixed-term Researcher (RTD-A), “Human Histology” - SSD BIO/7, University Vita-Salute San Raffaele, Milan, Italy

 

2021           Fixed-term Assistant Professor, “Pharmacology of ATMP” - SSD BIO/14, University of Piemonte Orientale “A. Avogadro”, Vercelli, Italy

 

PROFESSIONAL ACTIVITIES

 

2019           Project Leader, Gene and Neural Stem Cell Therapy for Lysosomal Storage Diseases Unit, San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget), Milan, Italy

 

2014           Postdoctoral Fellow, Laboratory of Chromatin and Gene Regulation during Development - INSERM UNIT U1163 - Imagine Institute of Genetic Diseases, Hôpital Necker-Enfants maladies, Paris, France

 

2011           Postdoctoral Fellow, Gene and Neural Stem Cell Therapy for Lysosomal Storage Diseases Unit - San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget), Milan, Italy

                  

2006           Ph.D. student and Postdoctoral Fellow, Laboratory of Neuroplasticity and Neuropathic Pain - University of Piemonte Orientale “A. Avogadro”, Novara, Italy

 

PROFESSIONAL HONORS

 

2022           NextGenerationEU-PNRR grant, Italian Ministry of University and Research

2022           BGTC AAV Biology research program (Co-PI), Foundation for the National Institutes of Health

2020           Marie Skłodowska-Curie actions (MSCA), Individual Fellowship - Horizon 2020

2019           Ricerca Finalizzata – Giovani Ricercatori 2019, Italian Ministry of Health

2019           Sanofi iAwards Europe 2019 (Co-PI)

2016           PRESTIGE COFUND European Union FP7 - Campus France

2006           National PhD Fellowship, Italian Ministry of Health and Research

 

 

 

PUBLICATIONS

 

1.  Cantore A., Fraldi A., Meneghini V., Gritti A. In vivo Gene Therapy to the Liver and Nervous System: Promises and Challenges. Front Med (Lausanne). 2022 Jan 18; 8:774618.

 

2. Ramadier S., … , Meneghini V.*, Miccio A.* Combination of lentiviral and genome editing technologies for the treatment of sickle cell disease. Mol Ther. 2022 Jan 5; 30(1):145-163. *Co-last and co-corresponding authors.

 

3.  Meneghini V.*, Peviani M., Zambonini G., Luciani M, Gritti A. Delivery Platforms for CRISPR/Cas9 Genome Editing of Glial Cells in the Central Nervous System. Front Genome Ed. 2021 Mar 3; 3:644319. *Corresponding author. Review.

 

4. Luciani M, Gritti A, Meneghini V.*. Human iPSC-Based Models for the Development of Therapeutics Targeting Neurodegenerative Lysosomal Storage Diseases. Front Mol Biosci. 2020 Sep 18; 7:224. *Corresponding author. Review.

 

5. Romano O., Petiti L., Felix T., Meneghini V., et al. GATA factor-mediated gene regulation in human erythropoiesis. iScience 2020 Mar 30;23(4):101018.

 

6. Weber L, Frati G, Felix T, Hardouin G, Casini A, Wollenschlaeger C, Meneghini V, et al. Editing a gamma-globin repressor binding site restores fetal hemoglobin synthesis and corrects the sickle cell disease phenotype. Sci Adv. 2020 Feb 12;6(7): eaay9392.

 

7. Lattanzi A., Meneghini V., et al. Optimization of CRISPR/Cas9 Delivery to Human Hematopoietic Stem and Progenitor Cells for Therapeutic Genomic Rearrangements. Mol Ther. 2019 Jan 2;27(1):137-150.

 

8. Frati G., Luciani M., Meneghini V., et al. Human iPSC-based models highlight defective glial and neuronal differentiation from neural progenitor cells in metachromatic leukodystrophy. Cell Death Dis. 2018, 9(6):698.

 

9. Antoniani C.*, Meneghini V.*, et al. Induction of fetal hemoglobin synthesis by CRISPR/Cas9-mediated editing of the beta-globin locus. Blood. 2018 Apr 26;131(17):1960-1973. *Co-first authors.

Commentary on Blood Journal: A chance to cut (the genome) is a chance to cure. Kara E. Montbleau and Vijay G. Sankaran. Blood 2018 131:1884-1885.

 

10. Meneghini V.*, Frati G.*, et al. Generation of Human Induced Pluripotent Stem Cell-Derived Bona Fide Neural Stem Cells for Ex Vivo Gene Therapy of Metachromatic Leukodystrophy. Stem Cells Transl Med. 2017 Feb;6(2):352-368. *Co-first authors.

 

11. Meneghini V., et al. Pervasive supply of therapeutic lysosomal enzymes in the CNS of normal and Krabbe-affect non-human primates by intracerebral lentiviral gene therapy. EMBO Mol Med. 2016 May 2;8(5):489-510.

 

12. Meneghini V., et al. The noradrenergic component in Tapentadol action counteracts MOR-mediated adverse effects on adult neurogenesis. Mol Pharmacol. 2014 May;85(5):658-70.

 

13. Meneghini V., et al. High-mobility group box-1 protein and beta-amyloid oligomers promote neuronal differentiation of adult hippocampal neural progenitors via receptor for advanced glycation end products/nuclear factor-kB axis: relevance for Alzheimer's disease. J Neurosci. 2013 Apr 3;33(14):6047-59.

 

14. Meneghini V., et al. A novel role for the Receptor for Advanced Glycation End-products in neural progenitor cells derived from adult SubVentricular Zone. Mol Cell Neurosci. 2010, 45(2):139-50.

 

15. Meneghini V., Odent S., Platonova N., Egeo A., Merlo G.R. Novel TBX3 mutation data in families with Ulnar-Mammary syndrome indicate a genotype-phenotype relationship: mutations that do not disrupt the T-domain are associated with less severe limb defects. Eur J Med Genet. 2006 Mar-Apr; 49(2):151-8.